This article discusses the current status and potential future developments in immunotherapy for genitourinary malignancies with insights from urologic oncology specialists Hyung L. Kim, MD, and Daniel P. Petrylak, MD.
In this article, urologists Scott E. Eggener, MD, and Stacy Loeb, MD, MSc, discuss the current applications for prostate cancer biomarkers and MRI, their impact on clinical practice, and future developments.
The role of protein- and cell-based urinary biomarkers for bladder cancer detection and surveillance is controversial, and in 2017 these assays have yet to come into widespread use among urologists. Their uptake is expected to increase, however, considering that the AUA/Society of Urologic Oncology “Guideline on Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer” that was released in 2016 identifies situations for using urinary biomarkers, according to Badrinath R. Konety, MD.
“The data from our study show that combination therapy [for metastatic renal cell carcinoma] may offer a much higher response rate with manageable side effects,” says study author Jianjun Gao, MD, PhD.
Findings of a retrospective study investigating variability of semen parameters after repeat testing in adolescents with varicocele indicate that a second semen analysis is warranted only when the sperm concentration is initially abnormal.
Single-stage anterior urethroplasty is feasible and safe when performed as a same-day outpatient procedure, even for men requiring combined substitution repairs, said University of Pittsburgh Medical Center urologists at the 2016 AUA annual meeting in San Diego.
Results of an international randomized phase III study show that pembrolizumab (Keytruda) as second-line therapy for advanced urothelial carcinoma provided superior overall survival and a better safety profile compared with commonly used chemotherapy options.
The perioperative surgical home is a promising model for delivering high-quality, cost-effective care for patients undergoing inpatient urologic procedures, according to the experience of urologists from Loma Linda University, Loma Linda, CA.